Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 02 2020
Historique:
received: 20 06 2019
revised: 06 08 2019
accepted: 01 10 2019
pubmed: 6 10 2019
medline: 18 11 2020
entrez: 6 10 2019
Statut: ppublish

Résumé

Precision oncology relies on the identification of molecular alterations, responsible for tumor initiation and growth, which are suitable targets of specific inhibitors. The development of FGFR inhibitors represents an edifying example of the rapid evolution in the field of targeted oncology, with 10 different FGFR tyrosine kinase inhibitors actually under clinical investigation. In parallel, the discovery of FGFR activating molecular alterations (mainly

Identifiants

pubmed: 31585937
pii: 1078-0432.CCR-19-2035
doi: 10.1158/1078-0432.CCR-19-2035
pmc: PMC7024606
mid: EMS84526
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Receptors, Fibroblast Growth Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-774

Subventions

Organisme : European Research Council
ID : 717034
Pays : International

Informations de copyright

©2019 American Association for Cancer Research.

Références

Cancer Discov. 2018 Jul;8(7):812-821
pubmed: 29848605
Toxicol Sci. 2013 Oct;135(2):451-64
pubmed: 23872713
Clin Cancer Res. 2017 Sep 15;23(18):5366-5373
pubmed: 28615371
JCO Precis Oncol. 2021 Jan 08;5:
pubmed: 34250419
Eur J Cancer. 2017 Dec;87:122-130
pubmed: 29145038
Oncogene. 2013 Jun 20;32(25):3059-70
pubmed: 22869148
Eur J Cancer. 2017 Aug;81:102-105
pubmed: 28623773
Biochemistry. 2004 Jan 27;43(3):629-40
pubmed: 14730967
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
ChemMedChem. 2019 Feb 19;14(4):494-500
pubmed: 30600916
Sci Transl Med. 2010 Dec 15;2(62):62ra93
pubmed: 21160078
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
Invest New Drugs. 2018 Jun;36(3):424-434
pubmed: 28965185
Invest New Drugs. 2017 Aug;35(4):451-462
pubmed: 28070720
Clin Cancer Res. 2019 May 1;25(9):2699-2707
pubmed: 30745300
Int J Cancer. 2017 Nov 1;141(9):1822-1829
pubmed: 28646488
Cancer Discov. 2012 Oct;2(10):948-59
pubmed: 22874768
Clin Cancer Res. 2013 Jul 1;19(13):3693-702
pubmed: 23658459
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Ann Oncol. 2017 Jun 01;28(6):1316-1324
pubmed: 29177434
J Clin Oncol. 2017 Jan 10;35(2):157-165
pubmed: 27870574
Clin Cancer Res. 2015 Jul 15;21(14):3307-17
pubmed: 25609060
J Thorac Oncol. 2019 Oct;14(10):1847-1852
pubmed: 31195180
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897
pubmed: 31088831
Eur Urol. 2017 Jun;71(6):858-862
pubmed: 28108151
Chem Commun (Camb). 2018 Oct 23;54(85):12089-12092
pubmed: 30298149
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Cancer Discov. 2013 Sep;3(9):1058-71
pubmed: 23744832
Lancet Oncol. 2015 Jun;16(6):686-94
pubmed: 25981814
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Mol Cancer Ther. 2016 Apr;15(4):533-47
pubmed: 27009213
Target Oncol. 2017 Aug;12(4):463-474
pubmed: 28589492
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Clin Oncol. 2015 Oct 20;33(30):3401-8
pubmed: 26324363
Br J Cancer. 2017 Nov 21;117(11):1592-1599
pubmed: 28972963
JAMA Dermatol. 2017 Jul 1;153(7):723-725
pubmed: 28538953
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Mol Cancer Ther. 2018 Jul;17(7):1526-1539
pubmed: 29654068
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
Clin Cancer Res. 2009 Jan 15;15(2):441-51
pubmed: 19147748
Ann Oncol. 2014 Mar;25(3):552-563
pubmed: 24265351
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Cancer Discov. 2019 Aug;9(8):1064-1079
pubmed: 31109923
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139

Auteurs

Francesco Facchinetti (F)

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.

Antoine Hollebecque (A)

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.

Rastislav Bahleda (R)

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.

Yohann Loriot (Y)

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Ken A Olaussen (KA)

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France.

Christophe Massard (C)

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.

Luc Friboulet (L)

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France. Luc.FRIBOULET@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH